Mobile Menu

Gene Editing Quality Control – From Humanised Mice to Engineered Human Cells

When: March 4, 2021 Time: 2:00 pm

The ease of new gene editing technologies has opened opportunities to explore in more detail the genetic underpinnings of disease, establish more relevant study models, and develop novel advanced therapies.

As essential yet often overlooked aspect of that work is validating edits, which is the main focus of this webinar.

This webinar brings you presentations, followed by live Q&A, from two distinguished speakers focusing on gene editing quality control:

Part 1

Presentation: Genomically Humanised Mouse Models of Neurodegenerative Disease

Tom Cunningham, Senior Investigator Scientist, MRC (Medical Research Council)

Dr Tom Cunningham and his team humanise mouse models to understand the genetics of ALS, and use a technology called Xdrop® to validate them.

Part 2

Presentation: CRISPR Validation and Resolving Complex Genomics Landscapes with Xdrop®

Peter Mouritzen, Vice President Application and Market Development, Samplix

Dr Peter Mouritzen explains how Xdrop® enriches long stretches of DNA as part of a sequencing strategy.

Part 3

Live Q&A: Our two speakers will answer your questions and share wider perspectives on gene editing quality control.

What you will take away from the webinar

  • How engineered mouse models can help reveal detailed genetic underpinnings of disease
  • The importance of validating gene edits
  • An overview of current gene editing validation methods and how they handle complex genomic regions
  • Genomic approaches capable of coupling target enrichment and long-read sequencing
  • The principle and outcomes of indirect sequence capture


Webinar Registration

This webinar has been made possible with the kind support of our partner, Samplix. We encourage anyone interested in finding out more about the technology discussed in this webinar to visit the Samplix website.

Image by Pete Linforth from Pixabay


Peter Mouritzen Peter Mouritzen, Vice President Application and Market Development, Samplix

Tom Cunningham Tom Cunningham, Senior Investigator Scientist, MRC (Medical Research Council)

More on these topics

CRISPR / Gene Editing / Model

Article Search